tbuckley/cabot-search huggingface dataset:
Abstract 2647: Influence of quercetin-rich foods intake on microRNA expression in EAGLE lung cancer tissues
Authors: Tram K. Lam
Journal: Cancer Research (2012)

Abstract Background: Lung cancer is one of the most common cancers worldwide and has the highest cancer-related mortality rate. Dietary factors may contribute to lung carcinogenesis. Epidemiologic studies, including the Environment and Genetics in Lung Cancer Etiology (EAGLE) study, have reported increased consumption of quercetin-rich foods to be inversely associated with lung cancer incidence. Although experimental studies suggest that quercetin might affect microRNA (miRNA) expression, this mechanism has not been fully examined. We investigated this hypothesis in quercetin-related lung carcinogenesis using lung cancer tissues. Methods: miRNA expression data were derived from formalin-fixed paraffin-embedded tissue samples in 264 lung (144 adenocarcinoma and 120 squamous cell carcinoma) cases from EAGLE using a custom-made, two-channel oligo array. Quercetin-rich foods were derived from food frequency questionnaire. Individuals were categorized into high and low consumers based on sex-specific tertiles of quercetin-rich food intake. We compared the expression of miRNAs (n=198) between lung cancer cases consuming high-versus-low quercetin-rich food intake using multivariate ANOVA test. We identified miRNAs whose expression differentiated high and low consumption (p-value&amp;lt;0.05), and further grouped them based on their biological function using MiRBase release 17.0. miRNA families were analyzed using Functional Class Scoring (FCS). All analyses were conducted for adenocarcinoma and squamous cell carcinoma separately. Further analyses included stratification by smoking status (former and current smokers only). Results: We found that miRNA expression of 56 miRNAs significantly distinguished lung cancer cases who consumed high-versus-low quercetin-rich foods in tumor tissue within smoking-specific histological subtypes (p-value&amp;lt;0.05). FCS analyses of these miRNAs identified the let-7 family to strongly differentiate between high-versus-low quercetin-rich cases (p-value&amp;lt;0.001), followed by miR-146, miR-125, miR-26, and miR-17 (p-value&amp;lt;0.05). Conclusions: We observed differential expression of key biologically functional miRNAs between high-versus-low consumers of quercetin-rich foods. Our findings, the first of this kind, warrant confirmation from larger studies. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 2647. doi:1538-7445.AM2012-2647
COMPARISON OF RIVAROXABAN OR WARFARIN USE FOR VENOUS THROMBOEMBOLISM ON INPATIENT LENGTH OF STAY
Authors: Steven Deitelzweig, Jeffrey Kline, Jay M. Margolis, Monika Raut, Oth Tran, David Smith, Concetta Crivera, Brahim Bookhart, Jeff Schein, William Olson
Journal: Journal of the American College of Cardiology (2016)
PWE-243 Reassessment of Crohn's disease treated with 12 months of anti-TNF therapy: a tertiary centre experience
Authors: R Dart, N Griffin, K Taylor, J Duncan, M Sastrillo, S Anderson, J Sanderson, P M Irving
Journal: Gut (2012)

Introduction Anti-TNF therapy (ATT) is increasingly used in Crohn's disease (CD) in the UK. However, because of its expense, NICE guidance recommends that after a year of treatment, responders should be reassessed and withdrawal of treatment considered if they are in remission. We report our experience in a tertiary referral centre of reassessment after 1 year of ATT and of factors leading to continuation or withdrawal of treatment. Methods We performed a 12-month retrospective review of patients with CD who had received ATT for >12 months by 31 December 2011. Reassessment was defined as having undergone one or more of the following investigations aimed at assessing disease activity: endoscopy, examination under anaesthesia, MRI or faecal calprotectin (FC). Results of investigations and outcome were recorded. Results 91 patients (infliximab n=55, adalimumab n=36) were included of whom 80% (73/91) had their disease reassessed. Five patients were withdrawn from treatment (of whom one has already relapsed) and five are pending trial of withdrawal; two patients met criteria for withdrawal but required continuation for extra-luminal disease such as arthropathy. 84 (92%) continued therapy. 48 patients had endoscopic reassessment; mucosal healing (MH) was demonstrated in 25% (n=12), non-ulcerating inflammation in 40% (n=19) and ulceration in 35% (n=17). Of 12 with MH 3 withdrew from therapy and 3 are pending withdrawal. Of six patients who continue, two require ongoing ATT for arthropathy, three had radiologic evidence of activity, and one is undergoing further assessment. 24 patients had both endoscopy and MRI and 19 patients underwent MRI alone. Of the latter group, scans were normal in 21% (n=4), showed improvement but not resolution in 32% (n=6) and active disease in 47% (n=9). Of four normal scans, one patient was withdrawn, and 3 continue due to raised FC (n=1) or raised CRP (n=2). Disease was assessed by EUA in five patients, demonstrating active disease in four and quiescent disease in one who is pending trial of withdrawal. One patient continues on treatment on the basis of raised FC alone. One patient had mild mucosal inflammation on endoscopy and an unchanged MRI scan prior to withdrawal but relapsed within 4 months. Conclusion Reassessment after at least 12 months of ATT showed ongoing disease activity in the vast majority (84%). Withdrawal was considered appropriate in only 13%. In patients with distal ileal and/or colonic disease, endoscopy is currently our mainstay of reassessment while for those with small bowel disease interval change on MRI is used. The role of CRP and FC remain to be defined. Competing interests None declared.
LONG-TERM CLINICAL OUTCOMES IN PATIENTS WITH ST-SEGMENT ELEVATION ACUTE MYOCARDIAL INFARCTION COMPLICATED BY CARDIOGENIC SHOCK
Authors: Tetsuma Kawaji, Hiroki Shiomi, Takeshi Morimoto, Yutaka Furukawa, Yoshihisa Nakagawa, Kazushige Kadota, Kenji Ando, Tetsu Mizogucgi, Mitsuru Abe, Mamoru Takahashi, Takeshi Kimura
Journal: Journal of the American College of Cardiology (2016)
Paroxysmal Hypertension in Spinal-Cord Injuries
Authors: Charles E. Thompson, A. Calhoun Witham
Journal: New England Journal of Medicine (1948)

THE purpose of this paper is to report on the clinical significance of a little known, but constantly occurring, phenomenon in high spinal-cord lesions. Mass sympathetic discharge, occurring either in conjunction with "mass reflex" or alone in response to various stimuli, has been noted for many years and was first clinically recorded in the classic papers of Head and Riddoch.1 Since sweating is the most obvious manifestation of this activity, the mass sympathetic discharge has usually been incompletely designated and has received much attention as "spinal reflex sweating."2 That the vasomotor component and in particular the severe hypertension may well . . .
Abstract P4-09-06: Breast Cancer Prognosis Is Inherited Independently of Patient, Tumor and Treatment Characteristics
Authors: E Rapiti, M Hartman, M Usel, S Benhamou, R Schaffar, I Neyroud-Caspar, K Czene, G Vlastos, PO Chappuis, C Bouchardy, H. Verkooijen
Journal: Cancer Research (2010)

Abstract Fondation Jean Dausset, Paris, France; Karolinska Institute, Stockolm, Sweden; Geneva University Hospitals, Switzerland Introduction: Several studies have suggested that survival of breast cancer is inherited, but none has assessed if this observation is linked to shared tumor characteristics or type of treatment. We studied the association of survival among first-degree relatives (FDRs) with breast cancer, taking into account characteristics of patients, tumors and treatments. Methods: In the population-based Geneva Breast Cancer Registry, we identified 162 pairs of FDRs diagnosed with breast cancer. Based on the breast cancer specific survival status of their proband (i.e. the mother or older sister), we categorized FDRs into poor, medium and good familial survival risk groups. We compared patient, tumor and treatment characteristics between categories and calculated standardized mortality ratios (SMRs) and adjusted disease specific mortality for each group. Results: Breast cancer patients in the poor familial survival risk group were more likely to be diagnosed at later stages than those in the good familial survival risk group. Similarly, they had higher SMRs than those in the medium and good survival risk groups (18.7, 95% Confidence Interval [CI]: 9.4-33.5 versus 16.5 95% CI: 7.6-31.4 and 9.4, 95% CI: 3.4-20.3, respectively). After adjustment for prognostic factors, women in the poor familial survival risk group were almost five times more likely to die of breast cancer than those in the good survival risk group (adjusted Hazard Ratio 4.8, 95% CI: 1.4-16.4). Conclusion: This study shows that breast cancer prognosis clusters within families, and suggests that the hereditary component is independent of patient, tumor characteristics and type of treatment. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P4-09-06.
RECURRENT ISCHEMIC CARDIO/CEREBROVASCULAR EVENTS AMONG PATIENTS WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION: INSIGHTS FROM THE AMI-QUEBEC REGISTRY
Authors: Thao Huynh, Roxanne Gagnon, Umair Iftikhar, Stéphane Rinfret, Samer Mansour, Martine Montigny, Marc Afilalo, Simon Kouz, Michel Nguyen, Richard Harvey, Mark Eisenberg, Claude Lauzon, Philippe L'Allier, Jean Claude Tardif, Erick Schampaert
Journal: Journal of the American College of Cardiology (2016)
Surgical Resident Duty-Hour Rules — Weighing the New Evidence
Authors: John D. Birkmeyer
Journal: New England Journal of Medicine (2016)

Surgical training has always been hard on residents. During my own residency more than 20 years ago, 100-hour workweeks and in-house call every other night were routine. A resident's life outside the hospital was simply not a priority. Residency may be even harder on patients. A large body of research has linked sleep deprivation in resident physicians to poor performance in neurobehavioral testing and, more alarmingly, to higher rates of attention failure in patient care.1,2Reacting to concerns about both resident well-being and patient safety, the Accreditation Council for Graduate Medical Education (ACGME) implemented duty-hour reforms in 2003 that . . .
MS-15 * THE IMPACT OF HISTOPATHOLOGIC AND RADIOLOGIC CHARACTERISTICS IN CLINICAL OUTCOME OF PATIENTS WHO UNDERWENT SURGERY FOR INTRACRANIAL MENINGIOMAS
Authors: G. Klironomos, S. Larjani, A. Mansouri, A. Ghare, A. Kilian, K. Aldape, G. Zadeh
Journal: Neuro-Oncology (2014)

INTRODUCTION: Meningiomas are common intracranial neoplasms with variability in their clinical presentation, biological behavior and response to treatment. PURPOSE: The aim of this study was to identify factors that predict the biological behaviour of meningiomas and patients' postsurgical outcome. METHODOLOGY: We retrospectively reviewed 415 meningiomas cases who had undergone surgical resection at Toronto Western Hospital between January 2007 to June 2013. Our cohort consisted of 162 males and 253 females. We reviewed clinical, radiological, and pathological reports, and collected the following data for statistical analysis: patients' sex, age, tumor grade-location, presence of peritumoral edema prior to surgical resection, tumors' largest diameter as a clinical measure of tumor size and history of radiation. All analyses were performed using IBM SPSS 20.0. RESULTS: The incidence of peritumoral edema was significantly higher in males (75%) than in females patients (52%) (p = 0.007). Meningioma location was associated with presence of edema (p < 0.001): olfactory meningiomas showed the highest incidence of edema (71.4%) followed by convexity meningiomas (62%), and sphenoid wing meningiomas (72%) (p < 0.001). Tumors with larger diameters (4.3cm vs. 3.5cm) were likely to have peritumoral edema (p = 0.001). The history of radiation was significantly correlated with peritumoral brain edema (76.4%, p = 0.003). The presence of residual tumor after surgical resection was more likely in meningiomas with higher grades; residual tumor was most common in grade III meningioma (75%) followed by grade II (29.3%), and grade I (17.7%) (p = 0.008). In radiation induced meningiomas the incidence of residual was 41.1%. Also, the grade of tumor was significantly correlated with the incidence of recurrence; grade III meningiomas showed the highest incidence of recurrence (50%) followed by grade II (19.5%) and grade I (4.1%) (p < 0.001). CONCLUSION: The present study demonstrates that specific demographic, radiologic, and pathologic characteristics are significant predictors of tumor response to therapy, tumor recurrence and overall patient outcome.
Abstract 19228: Cost-effectiveness of the CardioMems Implantable Pulmonary Artery Pressure Monitoring System in Patients With Chronic Heart Failure
Authors: Alexander T Sandhu, Jeremy D Goldhaber-Fiebert, Mintu P Turakhia, Daniel W Kaiser, Paul A Heidenreich
Journal: Circulation (2015)

Background: For management of heart failure, the value of the CardioMems device remains uncertain. We assessed the cost-effectiveness of the CardioMems device. Methods: We developed a Markov model to determine quality-adjusted life-years (QALYs), cost, and cost-effectiveness of patients with heart failure receiving CardioMems implantation compared to those with routine care. In the main case analysis, we modeled the intervention in the CHAMPION trial cohort, which included patients with NYHA Class III heart failure with a heart failure hospitalization within the past twelve months. We also performed subgroup analyses of patients with preserved ejection fraction or reduced ejection fraction, and a scenario analysis of a second cohort of patients from the CHARM trials with a previous heart failure hospitalization. We obtained event rates and utilities from published trial data; we used costs from literature estimates and Medicare payment data. The main case analysis was calibrated to the hospitalization and survival rates of the CHAMPION trial. Results: In the CHAMPION trial main case analysis, CardioMems reduced lifetime hospitalizations (2.37 versus 3.27), increased months of survival (67 versus 62), increased QALYs (2.66 versus 2.38) and increased costs ($171,132 versus $154,084), yielding a cost of $59,520 per QALY gained or $40,301 per life-year gained. The cost per QALY gained was $71,964 in patients with reduced ejection fraction compared to $34,899 in those with preserved ejection fraction. In less ill patients from the CHARM trials, which included patients with NYHA Class II heart failure, the device cost increased to $110,565 per QALY gained. If the device cost decreased from $17,500 in the main case analysis to $15,000, the intervention would cost less than $50,000 per QALY gained. The duration of effectiveness was initially assumed to be lifelong; if less than 29 months, CardioMems would cost more than $150,000 per QALY gained. Conclusion: The CardioMems device is cost-effective in populations similar to the CHAMPION trial, with a cost of less than $100,000 per QALY gained, if durability of device effectiveness is sustained. Post-marketing surveillance data on the device’s durability will further clarify its value.
A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer
Authors: M. Ueno, T. Okusaka, Y. Omuro, H. Isayama, A. Fukutomi, M. Ikeda, N. Mizuno, K. Fukuzawa, M. Furukawa, H. Iguchi, K. Sugimori, J. Furuse, K. Shimada, T. Ioka, S. Nakamori, H. Baba, Y. Komatsu, M. Takeuchi, I. Hyodo, N. Boku
Journal: Annals of Oncology (2015)

We evaluated the efficacy and toxicity of adding oral leucovorin (LV) to S-1 when compared with S-1 monotherapy in patients with gemcitabine-refractory pancreatic cancer (PC).Gemcitabine-refractory PC patients were randomly assigned in a 1:1 ratio to receive S-1 at 40, 50, or 60 mg according to body surface area plus LV 25 mg, both given orally twice daily for 1 week, repeated every 2 weeks (SL group), or S-1 monotherapy at the same dose as the SL group for 4 weeks, repeated every 6 weeks (S-1 group). The primary end point was progression-free survival (PFS).Among 142 patients enrolled, 140 were eligible for efficacy assessment (SL: n = 69 and S-1: n = 71). PFS was significantly longer in the SL group than in the S-1 group [median PFS, 3.8 versus 2.7 months; hazard ratio (HR), 0.56; 95% confidence interval (CI), 0.37-0.85; P = 0.003]). The disease control rate was significantly higher in the SL group than in the S-1 group (91% versus 72%; P = 0.004). Overall survival (OS) was similar in both groups (median OS, 6.3 versus 6.1 months; HR, 0.82; 95% CI, 0.54-1.22; P = 0.463). After adjusting for patient background factors in a multivariate analysis, OS tended to be better in the SL group (HR, 0.71; 95% CI, 0.47-1.07; P = 0.099). Both treatments were well tolerated, although gastrointestinal toxicities were slightly more severe in the SL group.The addition of LV to S-1 significantly improved PFS in patients with gemcitabine-refractory advanced PC, and a phase III trial has been initiated in a similar setting.Japan Pharmaceutical Information Center: JapicCTI-111554.
Abstract P2-02-09: The Effect of Breast-MRI in Work-Up of Primary Operable Breast Cancer
Authors: J Huttenhuis, R Bourez, I Faneyte, E. Kouwenhoven
Journal: Cancer Research (2010)

Abstract Background: Breast magnetic resonance imaging (MRI) is becoming an often-utilized examination in the preoperative planning for breast cancer. However, it is not yet accepted as a routine examination for all breast cancer patients due to the lack of data regarding whether breast MRI has any effect on recurrence or survival. Aim: The aim of this study is to evaluate the effect of MRI on surgical management in operable breast cancer. Methods: From April 2008 till January 2010 consecutive primary operable breast cancer patients had a preoperative breast-MRI in addition to regular mammography and ultrasonography. Additional lesions newly found by MRI were evaluated with a target ultrasound and if needed biopsied. Moreover MRI tumor size was compared to mammographic and ultrasonographic tumor size. Blinded for MRI results and the performed surgical plan, surgical management based on traditional radiological work-up was determined retrospectively by 2 surgeons. Change of surgical plan by MRI was subsequently analysed. Accuracy of MRI based surgical plan was evaluated by comparing definitive pathology. Results Hundred ninety eight consecutive patients were analyzed. Median age was 59 years (23-82). Additional ipsilateral and contralateral suspicious lesions were detected by MRI in 53 patients (27%). Twenty two patients had additionally target-ultrasonography: 5 lesions were not found, 4 lesions had benign aspect. Five out of 13 biopsied patients had second breast cancer, 3 patients had contralateral breast cancer and 2 patients had multicentric breast cancer. In 31 patients no further evaluation was performed because the new focus was supposed to be a satellite (n=12) or mastectomy was already chosen to be done (n=19). There was a change in surgical plan due to MRI results in 35 of 198 patients (18%), all of whom received more extensive surgery than previously planned: in 17 patients mastectomy was performed instead of lumpectomy, 15 patients had a more extensive lumpectomy. Three patients had contralateral surgery for breast cancer. In 24 patients (69%) MRI based surgical plan was confirmed by definitive pathology. In 11 patients MRI overestimated tumor size or misinterpreted a satellite lesion. Conclusion. Breast MRI contributes to a significantly change of surgical plan. However, false-positive findings are frequent. Therefore, in unselected primary operable breast cancer patients routine implementation of breast MRI is not right away justified. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P2-02-09.
Indomethacin in the Treatment of Premature Labor
Authors: Kenneth J. Moise, James C. Huhta, Dawod S. Sharif, Ching-Nan Ou, Brian Kirshon, Nathan Wasserstrum, Lorraine Cano
Journal: New England Journal of Medicine (1988)

Indomethacin is a potent agent in the treatment of premature labor, but its use has been limited because of concern about its constrictive effects on the fetal ductus arteriosus. To study these effects we used serial fetal echocardiography in 13 pregnant women in premature labor who received indomethacin according to three different dose schedules, ranging from 100 to 175 mg per day, for a maximum of 72 hours. The gestational ages of the fetuses ranged from 26.5 to 31.0 weeks. The detection of ductal constriction in 7 of the 14 fetuses by echocardiography led to the discontinuation of indomethacin. Three fetuses also had tricuspid regurgitation. There was no statistically significant difference between the mean (+/- SEM) gestational age of the fetuses with ductal constriction and that of those without constriction (29.3 +/- 0.59 and 28.4 +/- 0.52, respectively). There was no relation between serum indomethacin levels in the mothers and ductal constriction. In all seven fetuses affected, ductal constriction had resolved by the time they were restudied 24 hours after the discontinuation of indomethacin. Persistent fetal circulation was not detected in any of the 11 neonates studied after delivery. Indomethacin used to treat premature labor appears to cause transient constriction of the ductus arteriosus in some fetuses, even after short-term use.